Healthcare & Life Sciences

REPRESENT-PF Registry, Observational, PFA Atrial Fibrillation

NIH ClinicalTrials.gov registered the REPRESENT-PF observational registry (NCT07535268), a pragmatic prospective single-arm multi-center study evaluating FDA-approved Boston Scientific FARAWAVE Pulsed Field Ablation catheters for treatment of atrial fibrillation in underrepresented minority patients. All data collected will be standard of care. Conditions include persistent and paroxysmal atrial fibrillation.

Cancer Exercise App Trial for Post-Treatment Survivors

NIH registered a randomized controlled clinical trial (NCT07535918) evaluating the Cancer Exercise app (CEA) designed to promote physical activity among cancer survivors who have completed treatment. The 12-week home-based exercise program will randomize 240 participants into CEA or usual care groups to measure intervention effects on physical activity levels. The trial is registered with anticipated completion in April 2026.

Boston Scientific Accolade Pacemaker Safety Action - Software Update SMR6

ANSM has published updated safety information regarding Boston Scientific Accolade family implantable pacemakers (Accolade, Proponent, Essentio, Altrua 2, CRT-P Visionist, and Valitude). The agency reports that Boston Scientific is deploying software update SMR6 to correct anomalies in the previous SMR5 update and prevent inappropriate triggering of safety mode. For pace-dependent patients whose devices have not been updated with SMR5 and have 4 years or less of remaining battery life, an appointment should be scheduled without delay. SMR6 may reduce battery longevity for devices with extended longevity (EL) batteries. New device packaging since March 2026 includes information about potentially reduced battery life.

Safety Notice Cryotubes Cryo.s Medical Devices by Greiner Bio-One

ANSM recorded safety action R2609958 concerning Cryotubes Cryo.s medical devices manufactured by Greiner Bio-One. The company has issued a safety communication dated 17/04/2026 to affected users. ANSM directs users to contact Greiner Bio-One directly for details and questions regarding the action.

Patch 4 Cover FSL Sim Tatoo Adhesive Patch Recall

ANSM recorded safety action R2611097 initiated by Capteur Protect for the Patch 4 Cover FSL Sim Tatoo adhesive patch used with glucose sensors. Users of affected products received notification letters from the company. The recall affects pharmacies, retail chains, and wholesale distributors in France.

MaaT013 Fecal Microbiota Allogeneic Pool Rectal Suspension Recall

ANSM and Clinigen Healthcare France have initiated a precautionary recall of six lots of MaaT013 (fecal microbiota allogeneic pool, rectal suspension). The recall follows discovery of a donor selection process non-compliance where a donor meeting exclusion criteria was included in stool collections used to manufacture the affected lots. Healthcare establishments holding affected lots (7P010/2410111, 7P010/2410092, 7P010/2410096, 7P010/2410109, 7P010/2503009, 7P010/2503012) should quarantine and return product to the manufacturer.

Olympus Gyrus ACMI Everest Cutting Forceps Lot Recall R2607996

ANSM registered safety action R2607996 concerning a lot withdrawal of Everest cutting forceps (pince coupante) manufactured by Olympus Gyrus ACMI. The recall was initiated by Olympus following notification to ANSM. Affected users received a direct communication from the manufacturer. This action targets hospital pharmacies and health establishments that hold the implicated lot.

Ohio SB 386 Proposes Replacing MCOs with ASO

Ohio Senators Louis Blessing and Beth Liston introduced Senate Bill 386, the 'Medicaid Savings Act,' proposing to replace the state's seven Medicaid Managed Care Organizations with Administrative Services Organization vendors paid flat fees instead of capitated rates. The bill, currently in Senate Medicaid Committee sponsor testimony, cites Connecticut's ASO transition and potential federal Medicaid cuts under HR1 as rationale.

DOJ Signals Intensifying California Healthcare Fraud Enforcement

DOJ and California Attorney General have intensified healthcare fraud enforcement targeting hospice and home health providers in California. The DOJ announced a $50 million hospice fraud takedown with eight arrests, a $270 million Medi-Cal fraud guilty plea, and AG Bonta dismantled a $267 million hospice fraud scheme with 21 suspects charged. US Attorney Bill Essayli stated this represents the beginning of increased enforcement activity, with additional charges and takedowns expected every few months.

FDA Removes 12 Peptides from Category 2, Schedules PCAC Review Meetings

FDA announced removal of 12 peptide bulk drug substances from Category 2 of its Section 503A bulk drug substances list, with removal effective approximately April 22, 2026. FDA will convene the Pharmacy Compounding Advisory Committee on July 23–24, 2026, and before the end of February 2027, to discuss whether these peptides should be added to the 503A bulks list. One peptide (GHK-Cu) is also being removed from Category 1 for the same reason.

California AG Bonta Backs Strict CPOM Rules for MSO-PC Arrangements

California Attorney General Rob Bonta filed an amicus brief in Art Center Holdings v. WCE CA Art, LLC supporting strict interpretation of California's corporate practice of medicine (CPOM) prohibition for MSO-PC arrangements. The brief argues that contractual provisions giving MSOs the unilateral ability to replace physician-owners or control equity transfer create a 'captive PC' and violate CPOM. The filing aligns with S.B. 351 (enacted October 6, 2025), which expands state oversight of private equity and hedge fund involvement in physician practices.

DOJ Establishes National Fraud Enforcement Division, Consolidates Healthcare and Tax Fraud Enforcement

Acting U.S. Attorney General Todd Blanche announced the creation of the National Fraud Enforcement Division (NFED) on April 7, 2026, consolidating control over the Tax Section, Health Care Fraud Unit, and Market, Government and Consumer Fraud Unit under a new assistant attorney general. The division will centralize case tracking, mandate embedded prosecutors in all U.S. Attorney districts within 21 days, and create a National Fraud Detection Center to proactively identify fraud in taxpayer-funded programs including Medicare and Medicaid. The Civil Division must designate a liaison within 14 days and the Office of Legal Policy must evaluate further realignment within 120 days.

Q1 2026 Hatch-Waxman ANDA Settlements Chart

Robins Kaplan LLP summarizes reported settlements in federal district court Hatch-Waxman ANDA patent litigation cases for Q1 2026. The chart covers 13 settlement summaries involving brand-name drugs including Jardiance, Spravato, Xarelto, Xifaxan, Wakix, and others, documenting case names, patent numbers, and publicly available settlement terms such as consent judgments, injunctions, and dismissal provisions.

Sixth Circuit Holds Tennessee PBM Network and Steering Rules Are ERISA-Preempted

The Sixth Circuit held that Tennessee's PBM laws requiring any-willing-pharmacy access and prohibiting differential copays and steering incentives are ERISA-preempted as applied to self-funded ERISA plans. The court found these laws impermissibly dictate plan structure and administration rather than merely regulating costs. The ruling establishes that employers sponsoring self-funded ERISA plans and their PBMs cannot be compelled to include all willing pharmacies or prohibited from tiered cost-sharing.

Ohio Senate Bill 109 Sexual Misconduct Policy Changes

Ohio Senate Bill 109 (SB 109), effective March 21, 2025, substantially amends state law to strengthen the State Medical Board of Ohio's authority over licensed healthcare providers. The law shortens reporting timeframes from 60 to 30 days for healthcare facilities, providers, and professional associations; authorizes the Board to summarily suspend licenses for felony charges; requires Board providers on probationary orders to disclose their status to patients; expands criminal code sex offense provisions; and prohibits unauthorized intimate examinations on anesthetized or unconscious patients.

State Medical Board of Ohio Meeting Schedule, March 10-11, 2026

The State Medical Board of Ohio has published its meeting schedule for March 10-11, 2026. The Respiratory Care Advisory Council will meet virtually on March 10 at 2 p.m. On March 11, the Emerging Practice Trends Committee and the Board Meeting will be held in-person at the Rhodes State Office Tower. Meetings are open to the public and will not impose any compliance obligations.

Board Meetings Set for April 2026

The State Medical Board of Ohio has published its April 2026 public meeting schedule. Meetings include the Dietetics Advisory Council (April 6), Quality Assurance Committee, Emerging Practice Trends Committee, Board Meeting, and Compliance Committee (April 8), and the Acupuncture Advisory Council (April 15). Most meetings are in-person at Rhodes State Office Tower; some advisory councils meet virtually.

Monthly Board Meeting Scheduled for May 13, 2026 in Columbus

The State Medical Board of Ohio has scheduled its monthly board meeting for Wednesday, May 13, 2026, at 10:00 AM at the Rhodes State Office Tower, 30 East Broad Street, 3rd Floor, Columbus, OH 43215. The Board comprises twelve members: nine physicians (seven MD, one DO, one DPM) and three non-physician public members, all appointed by the Governor to five-year terms. The meeting is open to the public.

Jonathan Shakesprere Educational Permit #933 Consent Order

The West Virginia Board of Medicine issued a Consent Order against Jonathan Shakesprere's Educational Permit #933 on October 27, 2025. This consent action resolves a disciplinary matter concerning the medical professional's educational permit. Specific terms of the consent order are documented in the linked PDF.

WV Physician Discipline Report 1953-1991

West Virginia Board of Medicine published historical physician discipline records from 1953-1991, listing approximately 100+ cases of disciplinary actions against medical practitioners including podiatrists. The report contains names, case dates, and individual identification numbers for public reference. Cases span from October 1953 through July 1987, with clustering in 1986-1987.

David Mark Anderson MD Hearing Scheduled May 22

The West Virginia Board of Medicine has scheduled a public hearing for David Mark Anderson, MD on May 22, 2026 at 9:30 AM. This is a procedural notice announcing an upcoming administrative hearing. No specific charges or violations are detailed in the notice. Contact the Records Custodian at (304) 558-2921 for additional information.

Methods of Treating Locally Advanced or Metastatic Breast Cancers Using PD-1 Axis Binding Antagonists and Taxanes

The European Patent Office published patent application EP3310815A1, filed by F. Hoffmann-La Roche AG, covering methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists in combination with taxanes. Inventor is Daniel S. Chen. The publication includes IPC classifications covering therapeutic antibodies, antineoplastic compositions, and designated states for national phase entry.

Board of Dentistry Meeting Minutes, 2011-2025

The Hawaii Board of Dentistry has published archived meeting minutes from 2011 through 2025 on its official website. The listing includes regular board meetings and Rules Committee meetings held over the fifteen-year period. The page serves as an administrative archive and does not create any new compliance obligations or regulatory changes.

DIFFRACTIVE INTRAOCULAR LENSES FOR EXTENDED RANGE OF VISION

The European Patent Office publishes Patent EP3595584A1, granted to AMO Groningen B.V., covering diffractive intraocular lenses designed for extended vision range. The invention is classified under A61F 2/16, A61F 2/14, and G02C 7/04. The patent is designated across EU member states and EPO contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Bidirectional Prosthetic Finger with MCP Pivot (EP3785675A2)

The European Patent Office published patent application EP3785675A2, filed by RCM Enterprise, LLC, for a bidirectional prosthetic finger configured for abduction and adduction with MCP pivot. The A2 publication includes the search report and covers the mechanical design of the prosthetic device. The application designates 37 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.

Musculoskeletal Injury Evaluation Patent - Sym Healthcare - EP4646998A1

The European Patent Office published patent EP4646998A1, granted to Sym Healthcare Inc., covering a method for evaluating musculoskeletal injuries through 3D dynamic joint range of motion testing and static posture testing for postural abnormalities. The patent was published on April 8, 2026, and provides exclusive rights to the disclosed method.

Server Method Cognitive Therapy for Children With Disabilities

The European Patent Office published application EP2024210274A1 on April 8, 2026, covering a server-based cognitive and social therapy system for children with developmental disabilities. The invention uses emotion recognition, gesture analysis, and speech processing to monitor and deliver therapeutic interventions via a mobile application.

Evaluation Method and Device for Comparing Anti-Anxiety Medicine Effects, EP2024168475A1

The European Patent Office published patent application EP2024168475A1 covering an evaluation method and device for comparing anti-anxiety medicine effects with efficiency. The patent is classified under G16H 50/70 (healthcare informatics for diagnosis) and designates all EPO contracting states including AT, BE, CH, DE, DK, ES, FI, FR, GB, IT, NL, NO, PL, PT, SE, and others. The invention provides a systematic method for pharmaceutical researchers to assess and compare the efficacy of different anxiety treatments.

EP4642325A1 - Implantable Medical Device With Code Path Metrics

The European Patent Office granted Patent EP4642325A1 to Advanced Neuromodulation Systems, Inc. on April 8, 2026. The patent covers an implantable medical device system with code path metrics for neuromodulation applications. The invention relates to the technical fields of medical device monitoring and therapeutic stimulation systems.

European Patent Surgical Hub Spatial Awareness

The European Patent Office published patent EP3506292A1 for Ethicon LLC, titled 'Spatial Awareness of Surgical Hubs in Operating Rooms.' The patent, granted April 8, 2026, covers spatial tracking and awareness technologies for surgical hub systems used in medical procedures. The invention is classified under G16H 20/40 and G16H 40/63, relating to health informatics and computer-assisted surgery. The patent designates all major European states including DE, FR, GB, IT, ES, NL, BE, CH, and others.

IMPLANTABLE MEDICAL DEVICE (IMD) WITH CODE PATH METRICS

The European Patent Office granted European Patent Application EP4642527A1 to Advanced Neuromodulation Systems, Inc. for an implantable medical device with code path metrics. The invention relates to neuromodulation technology that tracks and analyzes software code execution paths within an implanted device. The patent is valid across 44 designated European contracting states.

Nestlé Patent EP3549139A1 for Personalized Nutritional Health Scoring System

The European Patent Office granted Société des Produits Nestlé S.A. Patent EP3549139A1 covering a system and methods for calculating, displaying, modifying, and using improved personalized nutritional health scores to assess and plan optimal diets. The patent application was published on April 8, 2026, with inventor Fabio Mainardi listed. Designated states include AT, BE, DE, DK, ES, FI, FR, GB, GR, and HU among other European countries. The patent is classified under G16H 50/30 and G16H 20/60 (Health Informatics).

EP4642324A1 Implantable Medical Device with Code Path Metrics

The European Patent Office published patent application EP4642324A1 for Advanced Neuromodulation Systems, Inc. The invention covers an implantable medical device (IMD) configured to collect and transmit code path metrics data. The application claims priority to multiple IPC classifications including A61N 1/36 (neural stimulation), A61N 1/372 (implantable device control), and G16H 40/40 (health informatics). The patent is designated across 34 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.

EP3616212A1 - Click Therapeutics AI Digital Health Patent

The European Patent Office published patent application EP3616212A1 for Click Therapeutics, Inc., covering systems, methods, and apparatuses for managing data in artificial intelligence software and mobile applications for digital health therapeutics. The invention is classified under IPC G16H (Health Informatics) with designations across 31 European states. This patent grant establishes intellectual property rights for AI-driven digital therapeutic technology in European markets.

Implantable Medical Device Code Path Metrics - EP4642528A1

The EPO published patent application EP4642528A1 for an implantable medical device system that captures code path metrics during device operation, filed by Advanced Neuromodulation Systems, Inc. The application covers neuromodulation devices utilizing machine learning to analyze device performance data. The designated states include all EU member states plus extended countries.

Two Men Charged for Running Fentanyl Lab in Residential Building

DEA New York Division Special Agent in Charge Farhana Islam announced criminal charges against two individuals for narcotics and firearms offenses related to operating an illegal fentanyl manufacturing operation in a residential building. The case involves coordination with the Department of Justice, Homeland Security Investigations, and the Southern District of New York U.S. Attorney's Office.

Anti-HER3 Antibody Drug Conjugate Patent by Beijing Sinotau Bio-Pharma

EPO published patent application EP4355787A1 for Anti-HER3 antibody drug conjugate compositions and methods by Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. The patent covers ADC technology targeting HER3 for cancer treatment with designated states spanning major European jurisdictions. Inventors include Zhong Xiaoyan, Li Zhe, and Zhu Jie.

Helix Biopharma Corp. Antibody-Urease Conjugates for Diagnostic and Therapeutic Use

The European Patent Office granted Patent EP2984170A1 to Helix Biopharma Corp. for antibody-urease conjugates for diagnostic and therapeutic purposes. The patent, with inventor Chao Heman, covers compositions classified under A61K 47/68, A61P 35/00, C07K 16/32, C12N 9/80, and C12N 9/96. The designated states include all EU member states and extension countries.

Plants Comprising Wheat G-Type Cytoplasmic Male Sterility Restorer Genes, Molecular Markers and Uses Thereof

The European Patent Office granted BASF SE Patent EP3429334A1 covering wheat plants comprising G-type cytoplasmic male sterility restorer genes and associated molecular markers. The patent is classified under IPC codes A01H, C12N, and C07K, covering biotechnology applications for plant genetics. The designation includes 31 states across the EU and beyond.

Microbial Consortia Patent EP3262151A1, Amvac Chemical Corporation

The European Patent Office published patent application EP3262151A1 titled 'Microbial Consortia' filed by Amvac Chemical Corporation. The patent relates to compositions and methods involving microbial consortia, classified under IPC C12N (microorganisms, fungi, algae), C05F (fertilizers), and A01N (biocides). The patent application designates all EU member states.

Modified Adeno-Associated Virus Capsid Patent EP4389880A1

The European Patent Office published patent application EP4389880A1 for Joint Stock Company Biocad, covering methods of obtaining modified adeno-associated virus (AAV) capsids. The patent is classified under IPC codes C12N 7/00, C12N 15/86, C07K 14/005, and others related to viral vectors and genetic engineering. The patent designates all relevant European contracting states including Germany, France, Italy, Spain, and the United Kingdom.

Microbial Consortia Patent Application EP3262152A1

The European Patent Office published patent application EP3262152A1 for Amvac Chemical Corporation, covering microbial consortia compositions and their applications in agriculture and chemical processing. The patent application includes claims for biological preparations, organic fertilizers, and related compositions. The designated states cover most European countries including DE, FR, GB, ES, IT, NL, and others.

Use of Cellulase to Improve Viscosity Control of Dissolving Pulp

The European Patent Office published patent application EP3365493A1 by Novozymes A/S for the use of cellulase enzymes to improve viscosity control of dissolving pulp. The patent covers methods of treating pulp with cellulase to achieve desired viscosity characteristics in paper manufacturing processes. The application was published April 8, 2026.

City of Hope Patents Phosphorothioated Oligodeoxynucleotide Compounds and Compositions

The European Patent Office published patent application EP3316894A1 for City of Hope covering phosphorothioated oligodeoxynucleotide compounds and pharmaceutical compositions for therapeutic use. The application classifies under IPC codes C12N 15/113 and A61K 31/713 relating to oligonucleotides and nucleic acid preparations. The publication establishes a priority date and makes the application available for opposition.

DNA Editing Using Single-Stranded DNA - EP3303585A1 Patent Grant

The European Patent Office published patent grant EP3303585A1 for DNA editing using single-stranded DNA. The patent names Board of Regents of the University of Nebraska and Tokai University Educational System as applicants. The invention covers biotechnology methods for DNA editing with applications in genetic research and development.

BASF SE Patents Wheat G-Type Cytoplasmic Male Sterility Restorer Genes

The European Patent Office published patent application EP3429335A1 on April 8, 2026, granting BASF SE exclusive rights to wheat G-type cytoplasmic male sterility restorer genes, molecular markers, and related uses. The patent covers biotechnology applications in plant breeding under IPC classifications C12Q, C07K, C12N, and A01H across all designated EPO member states.

Merthyr Tydfil Children's Services Consultation, Deadline 13 May

Care Inspectorate Wales (CIW) will conduct an assurance check of Merthyr Tydfil County Borough Council Children's Services in May 2026, reviewing the local authority's performance of Social Services duties under relevant legislation. CIW is seeking public feedback from service users by 13 May 2026 via online surveys, and findings will be published on the CIW website.

Three Victorians Arrested, $2M Steroids and Peptides Seized in Joint ABF-TGA Operation

The Australian Border Force and Therapeutic Goods Administration announced the arrest of three Victorians and seizure of over $2 million worth of Performance and Image Enhancing Drugs (PIEDs), including more than 10,000 vials and 600 tablets of steroids and peptide products. The eight-month joint investigation, which began in August 2025 following the interception of 640 vials, led to criminal charges against three individuals for importing Tier 1 Goods (PIEDs). The TGA warned that unapproved peptide products present serious safety risks including contamination, infection, and tissue damage.

Over 30,000 Illegal Vaping Goods Seized in Major TGA Operation, South-West Sydney

The TGA, assisted by NSW Police Force, seized over 30,000 illegal vaping goods from sites in Chipping Norton and Casula on 15 April 2026, with an estimated street value of $1.8 million. This enforcement action follows a significant investigation into unlawful online advertising, supply, and possession of commercial quantities of illegal vaping goods. The TGA warns that non-compliance with vaping offences under the Therapeutic Goods Act 1989 can result in penalties including up to 7 years imprisonment, or fines of up to $2.31 million for individuals and $23.1 million for corporations per offence.

Board of Medical Examiners Full Board Meeting - April 2026

The Montana Board of Medical Examiners has scheduled a full board meeting for April 24, 2026 from 10am to 4pm at 301 S Park Ave, 4th Floor, Large Conference Room. The meeting will be held in-person and virtually via teleconference. New agenda items may be added up to 48 hours before the meeting.